PATENT CLAIM ANALYSIS

Application Number: 16012992
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "001890"]

Abstract:
Described are assay methods, modules and kits useful in the detection, treatment and/or prevention of dementia and related conditions, including but not limited to Alzheimer's disease and mild cognitive disorders.

Claim (Index 21):
The method of  claim 16  wherein said method further comprises measuring a level of an additional autoantibody to at least one supplemental biomarker in said sample, wherein said supplemental biomarker comprises one or more of the following: an A\u03b2 peptide, tau, a fragment or isoform of an A\u03b2 peptide or tau, or combinations thereof, and said first biomarker and said supplemental biomarker are different, and determining from said levels of autoantibody and additional autoantibody the presence, absence, and/or progression of Alzheimer's-related dementia and/or plaque formation in said patient.

Metadata:
- Claim Count in Document: 31.0
- Percentile: 94.0
- Lexical Diversity: 1.12903
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12867479', '12799484', '13874052', '14200020', '10982545']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7113427853022515
- 35 USC 102 Novelty (BERT): 0.5008768659149618
- Combined Prediction Score: 0.6902961933635225
- Mean Citation Score: 253.80111
- Max Citation Score: 263.87994
- Similarity Product: 226.29383523155445

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test